Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 169 to 176 of 176 entries
Sorted by: Best Match Show Resources per page
Precision medicine in oncology: what is it exactly and where are we?.

Personalized medicine

Le Tourneau C, Kamal M, Bièche I.
PMID: 30260312
Per Med. 2018 Sep;15(5):351-353. doi: 10.2217/pme-2018-0036. Epub 2018 Sep 27.

No abstract available.

Cite
Le Tourneau C, Kamal M, Bièche I. Precision medicine in oncology: what is it exactly and where are we?. Per Med. 2018;15(5):351-353doi: 10.2217/pme-2018-0036.
Le Tourneau, C., Kamal, M., & Bièche, I. (2018). Precision medicine in oncology: what is it exactly and where are we?. Personalized medicine, 15(5), 351-353. https://doi.org/10.2217/pme-2018-0036
Le Tourneau, Christophe, et al. "Precision medicine in oncology: what is it exactly and where are we?." Personalized medicine vol. 15,5 (2018): 351-353. doi: https://doi.org/10.2217/pme-2018-0036
Le Tourneau C, Kamal M, Bièche I. Precision medicine in oncology: what is it exactly and where are we?. Per Med. 2018 Sep;15(5):351-353. doi: 10.2217/pme-2018-0036. Epub 2018 Sep 27. PMID: 30260312.
Copy Download .nbib Format: NLM
Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.

The oncologist

Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM.
PMID: 28179575
Oncologist. 2017 Feb;22(2):144-151. doi: 10.1634/theoncologist.2016-0195. Epub 2017 Feb 08.

BACKGROUND: The increasing practicality of genomic sequencing technology has led to its incorporation into routine clinical practice. Successful identification and targeting of driver genomic alterations that provide proliferative and survival advantages to tumor cells have led to approval and...

Cite
Knepper TC, Bell GC, Hicks JK, et al. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist. 2017;22(2):144-151doi: 10.1634/theoncologist.2016-0195.
Knepper, T. C., Bell, G. C., Hicks, J. K., Padron, E., Teer, J. K., Vo, T. T., Gillis, N. K., Mason, N. T., McLeod, H. L., & Walko, C. M. (2017). Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. The oncologist, 22(2), 144-151. https://doi.org/10.1634/theoncologist.2016-0195
Knepper, Todd C, et al. "Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience." The oncologist vol. 22,2 (2017): 144-151. doi: https://doi.org/10.1634/theoncologist.2016-0195
Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist. 2017 Feb;22(2):144-151. doi: 10.1634/theoncologist.2016-0195. Epub 2017 Feb 08. PMID: 28179575; PMCID: PMC5330702.
Copy Download .nbib Format: NLM
[Current status and future prospect of internal medicine treatment for advanced esophageal cancer].

Zhonghua zhong liu za zhi [Chinese journal of oncology]

Wang F, Fan QX.
PMID: 27647396
Zhonghua Zhong Liu Za Zhi. 2016 Sep 23;38(9):655-9. doi: 10.3760/cma.j.issn.0253-3766.2016.09.004.

Esophageal cancer (EC) is one of common malignant tumors, and the incidence and mortality of EC in China rank the first place in the world. Because of the occult onset, the early atypical symptoms, and the lack of effective...

Cite
Wang F, Fan QX. [Current status and future prospect of internal medicine treatment for advanced esophageal cancer]. Zhonghua Zhong Liu Za Zhi. 2016;38(9):655-9doi: 10.3760/cma.j.issn.0253-3766.2016.09.004.
Wang, F., & Fan, Q. X. (2016). [Current status and future prospect of internal medicine treatment for advanced esophageal cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 38(9), 655-9. https://doi.org/10.3760/cma.j.issn.0253-3766.2016.09.004
Wang, F, and Fan, Q X. "[Current status and future prospect of internal medicine treatment for advanced esophageal cancer]." Zhonghua zhong liu za zhi [Chinese journal of oncology] vol. 38,9 (2016): 655-9. doi: https://doi.org/10.3760/cma.j.issn.0253-3766.2016.09.004
Wang F, Fan QX. [Current status and future prospect of internal medicine treatment for advanced esophageal cancer]. Zhonghua Zhong Liu Za Zhi. 2016 Sep 23;38(9):655-9. doi: 10.3760/cma.j.issn.0253-3766.2016.09.004. Chinese. PMID: 27647396.
Copy Download .nbib Format: NLM
Targeted Therapy and Immunotherapy for Melanoma in Japan.

Current treatment options in oncology

Namikawa K, Yamazaki N.
PMID: 30675668
Curr Treat Options Oncol. 2019 Jan 24;20(1):7. doi: 10.1007/s11864-019-0607-8.

OPINION STATEMENT: Melanoma has several clinically and pathologically distinguishable subtypes, which also differ genetically. Mutation patterns vary among different melanoma subtypes, and efficacy of immune-checkpoint inhibitors differs depending on the subtype of melanoma. In spite of the recent revolution...

Cite
Namikawa K, Yamazaki N. Targeted Therapy and Immunotherapy for Melanoma in Japan. Curr Treat Options Oncol. 2019;20(1):7doi: 10.1007/s11864-019-0607-8.
Namikawa, K., & Yamazaki, N. (2019). Targeted Therapy and Immunotherapy for Melanoma in Japan. Current treatment options in oncology, 20(1), 7. https://doi.org/10.1007/s11864-019-0607-8
Namikawa, Kenjiro, and Yamazaki, Naoya. "Targeted Therapy and Immunotherapy for Melanoma in Japan." Current treatment options in oncology vol. 20,1 (2019): 7. doi: https://doi.org/10.1007/s11864-019-0607-8
Namikawa K, Yamazaki N. Targeted Therapy and Immunotherapy for Melanoma in Japan. Curr Treat Options Oncol. 2019 Jan 24;20(1):7. doi: 10.1007/s11864-019-0607-8. PMID: 30675668; PMCID: PMC6344396.
Copy Download .nbib Format: NLM
Clonotyping for precision oncology.

Drug discovery today

Dang HX, Maher CA.
PMID: 26494143
Drug Discov Today. 2015 Dec;20(12):1464-9. doi: 10.1016/j.drudis.2015.10.010. Epub 2015 Oct 19.

Advances in identifying subpopulations of cancer cells and reconstructing the clonal evolution of tumors greatly enhance our understanding of the molecular events within a patient and their context relative to one another. In the rapidly unfolding era of personalized...

Cite
Dang HX, Maher CA. Clonotyping for precision oncology. Drug Discov Today. 2015;20(12):1464-9doi: 10.1016/j.drudis.2015.10.010.
Dang, H. X., & Maher, C. A. (2015). Clonotyping for precision oncology. Drug discovery today, 20(12), 1464-9. https://doi.org/10.1016/j.drudis.2015.10.010
Dang, Ha X, and Maher, Christopher A. "Clonotyping for precision oncology." Drug discovery today vol. 20,12 (2015): 1464-9. doi: https://doi.org/10.1016/j.drudis.2015.10.010
Dang HX, Maher CA. Clonotyping for precision oncology. Drug Discov Today. 2015 Dec;20(12):1464-9. doi: 10.1016/j.drudis.2015.10.010. Epub 2015 Oct 19. PMID: 26494143; PMCID: PMC4975004.
Copy Download .nbib Format: NLM
Releasing the brakes to fight cancer: The recent discovery of checkpoints has boosted the field of cancer immunotherapy.

EMBO reports

Weigmann K.
PMID: 27458238
EMBO Rep. 2016 Sep;17(9):1257-60. doi: 10.15252/embr.201643038. Epub 2016 Jul 25.

No abstract available.

Cite
Weigmann K. Releasing the brakes to fight cancer: The recent discovery of checkpoints has boosted the field of cancer immunotherapy. EMBO Rep. 2016;17(9):1257-60doi: 10.15252/embr.201643038.
Weigmann, K. (2016). Releasing the brakes to fight cancer: The recent discovery of checkpoints has boosted the field of cancer immunotherapy. EMBO reports, 17(9), 1257-60. https://doi.org/10.15252/embr.201643038
Weigmann, Katrin. "Releasing the brakes to fight cancer: The recent discovery of checkpoints has boosted the field of cancer immunotherapy." EMBO reports vol. 17,9 (2016): 1257-60. doi: https://doi.org/10.15252/embr.201643038
Weigmann K. Releasing the brakes to fight cancer: The recent discovery of checkpoints has boosted the field of cancer immunotherapy. EMBO Rep. 2016 Sep;17(9):1257-60. doi: 10.15252/embr.201643038. Epub 2016 Jul 25. PMID: 27458238; PMCID: PMC5007568.
Copy Download .nbib Format: NLM
Progress in systemic therapy for triple-negative breast cancer.

Frontiers of medicine

Mo H, Xu B.
PMID: 32789731
Front Med. 2021 Feb;15(1):1-10. doi: 10.1007/s11684-020-0741-5. Epub 2020 Aug 13.

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a heterogeneous genetic profile. Chemotherapy exhibits substantial activity in a small subset of these patients. Drug resistance is inevitable. Major progress has been made in the...

Cite
Mo H, Xu B. Progress in systemic therapy for triple-negative breast cancer. Front Med. 2020;15(1):1-10doi: 10.1007/s11684-020-0741-5.
Mo, H., & Xu, B. (2021). Progress in systemic therapy for triple-negative breast cancer. Frontiers of medicine, 15(1), 1-10. https://doi.org/10.1007/s11684-020-0741-5
Mo, Hongnan, and Xu, Binghe. "Progress in systemic therapy for triple-negative breast cancer." Frontiers of medicine vol. 15,1 (2021): 1-10. doi: https://doi.org/10.1007/s11684-020-0741-5
Mo H, Xu B. Progress in systemic therapy for triple-negative breast cancer. Front Med. 2021 Feb;15(1):1-10. doi: 10.1007/s11684-020-0741-5. Epub 2020 Aug 13. PMID: 32789731.
Copy Download .nbib Format: NLM
A Trial of Targeted Therapy.

International journal of radiation oncology, biology, physics

Thariat J.
PMID: 34273321
Int J Radiat Oncol Biol Phys. 2021 Aug 01;110(5):1265-1266. doi: 10.1016/j.ijrobp.2021.04.034.

No abstract available.

Cite
Thariat J. A Trial of Targeted Therapy. Int J Radiat Oncol Biol Phys. 2021;110(5):1265-1266doi: 10.1016/j.ijrobp.2021.04.034.
Thariat, J. (2021). A Trial of Targeted Therapy. International journal of radiation oncology, biology, physics, 110(5), 1265-1266. https://doi.org/10.1016/j.ijrobp.2021.04.034
Thariat, Juliette. "A Trial of Targeted Therapy." International journal of radiation oncology, biology, physics vol. 110,5 (2021): 1265-1266. doi: https://doi.org/10.1016/j.ijrobp.2021.04.034
Thariat J. A Trial of Targeted Therapy. Int J Radiat Oncol Biol Phys. 2021 Aug 01;110(5):1265-1266. doi: 10.1016/j.ijrobp.2021.04.034. PMID: 34273321.
Copy Download .nbib Format: NLM
Showing 169 to 176 of 176 entries